☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Calliditas
Calliditas Reports Results from P-IIb (TRANSFORM) Study of Setanaxib for Treating Primary Biliary Cholangitis
July 26, 2024
Calliditas’ Nefecon Meets its Primary Endpoint in P-III Trial (NefIgArd) for the Treatment of IgA Nephropathy
March 13, 2023
Calliditas’ Kinpeygo Receive EC's Marketing Authorization for the Treatment of Primary Immunoglobulin A Nephropathy
July 18, 2022
Calliditas Reports First Patient Randomization in P-IIb/III (TRANSFORM) Study for Primary Biliary Cholangitis
February 15, 2022
Calliditas’s Tarpeyo (budesonide) Receives the US FDA’s Accelerated Approval for the Treatment of IgA Nephropathy
December 15, 2021
PharmaShots Weekly Snapshots (August 09, 13, 2021)
August 13, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.